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MOLECULAR BASIS OF 
MITOCHONDRIAL DISEASE
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SIGNS AND SYMPTOMS
• THE AGES OF 5 AND 15 YEARS
• ATAXIA
• HEART DISEASE 
• SPINAL CORD AND PERIPHERAL NERVES DEGENERATE
• CEREBELLUM (AWKWARD, UNSTEADY MOVEMENTS AND IMPAIRED SENSORY 
FUNCTIONS)
Include loss of tendon reflexes, especially in the 
knees and ankles
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GENE THERAPY
A Potential New Therapeutic Approach for 
Friedreich Ataxia: Induction of Frataxin
Expression With TALE Proteins
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INCREASE FRATAXIN LEVELS THROUGH DRUG 
TREATMENTS, GENETIC ENGINEERING AND 
PROTEIN DELIVERY SYSTEMS
 The Friedreich’s Ataxia Research Alliance (FARA) 
 http://www.curefa.org/index.php
 http://www.fara.org.au/
